468
R. C. Bernotas et al.
PAPER
Anal. Calcd for C11H12N2O2: C, 64.69; H, 5.92; N, 13.72. Found: C,
64.67; H, 5.90; N, 13.66.
MS (CI; CH4): m/z (%) = 323 (100), 203 (35).
5-Benzyl-2-butyltetrahydroisoxazolo[2,3-a]pyrazin-4-one (16)
An additional portion of 1-hexene (0.37 mL, 3.0 mmol) was added
after 42 h. The crude product was purified by chromatography
(EtOAc) (to remove a small amount of unreacted nitrone 1) to give
16.
Cycloaddition of Nitrone 1 with Alkenes; General Procedure
A stirred solution of alkene (3.00 mmol) in CH2Cl2 (2.0 mL) under
nitrogen at r.t. (ca. 18 °C) was treated with nitrone 1 (204 mg, 1.00
mmol). The reaction mixtures were concentrated in vacuo when
TLC analysis using EtOAc as eluent indicated complete (or near
complete) consumption of nitrone. Reaction times were as shown in
Table 1. The residue after concentration was purified by flash chro-
matography to give the products. Ratios of diastereomers were de-
termined based on isolated products.
Yield: 263 mg (91%); Rf ca. 0.52 in EtOAc); off-white solid; mp
89–90 °C.
IR (KBr): 2935, 1637, 1499, 1454, 1264, 700 cm–1.
1H NMR (CDCl3): d = 7.35–7.22 (5 H), 4.69 (1 H, d, J = 14.6 Hz),
4.50 (1 H, d, J = 14.6 Hz), 4.23 (1 H, m), 4.12 (1 H, app. t, J = 8 Hz),
3.35–3.06 (4 H), 2.64 (1 H, m), 2.38 (1 H, m), 1.65 (1 H, m), 1.52
(1 H, m), 1.45–1.35 (4 H), 0.90 (3 H, t, J = 6.9 Hz).
5-Benzyl-2-phenyltetrahydroisoxazolo[2,3-a]pyrazin-4-one
(13)
The product was purified by chromatography (EtOAc–hexane,
75:25) to give 13.
13C NMR (CDCl3): d = 168.3, 136.1, 128.6, 127.9, 127.5, 76.6, 63.9,
49.4, 47.8, 42.6, 38.8, 34.6, 27.9, 22.4, 13.8.
Yield: 270 mg (87%); off-white solid; Rf ca. 0.38 in EtOAc; mp
94.5–96.0 °C.
MS (CI; CH4): m/z (%) = 289 (100), 203 (27).
HRMS (TOF ESI+): m/z calcd for C17H24N2O3 (+H): 289.1910;
found: 289.1903.
IR (KBr): 3437, 3031, 1635, 1497, 1260, 747, 698 cm–1.
1H NMR (CDCl3): d = 7.38–7.26 (10 H), 5.24 (1 H, dd, J = 6.1, 8.3
Hz), 4.69 (1 H, d, J = 14.5 Hz), 4.59 (1 H, d, J = 14.6 Hz), 4.30 (1
H, dd, J = 6.8, 8.3 Hz), 3.46 (1 H, m), 3.35–3.25 (3 H, m), 3.04 (1
H, ddd, J = 6.5, 8.5, 12.9 Hz), 2.74 (1 H, ddd, J = 6.1, 8.6, 12.9 Hz).
13C NMR (CDCl3): d = 168.1, 141.1, 136.2, 128.8, 128.6, 128.1,
127.9, 127.7, 126.1, 78.2, 64.3, 49.7, 48.2, 42.6, 42.0.
5-Benzyl-2-hydroxymethyltetrahydroisoxazolo[2,3-a]pyrazin-
4-one (17a) and 5-Benzyl-2-hydroxymethyltetrahydroisoxazo-
lo[2,3-a]pyrazin-4-one (17b)
The crude product was purified eluting with EtOH–EtOAc (10:90)
to separate the two diastereomers.
MS (CI; CH4): m/z (%) = 309 (100).
Compound 17a
Anal. Calcd for C19H20N2O2: C, 74.00; H, 6.54; N, 9.08. Found: C,
73.97; H, 6.68; N, 9.07.
Yield: 222 mg (85%); tan solid; Rf ca. 0.21 in EtOAc; mp 129–
131 °C.
IR (KBr): 3204, 2929, 1646, 1492, 1449, 1352, 1260, 1092, 748,
700 cm–1.
1H NMR (CDCl3): d = 7.37–7.22 (5 H), 4.60 (2 H, s), 4.35 (1 H, m),
4.10 (1 H, dd, J = 5.9, 8.7 Hz), 3.73 (1 H, dd, J = 2.7, 11.9 Hz), 3.62
(1 H, dd, J = 5.0, 11.7 Hz), 3.49 (1 H, m), 3.25–3.15 (3 H), 2.64 (2
H, m), 1.32 (1 H, br s).
5-Benzyl-2-(4-methoxyphenyl)tetrahydroisoxazolo[2,3-a]pyr-
azin-4-one (14)
Crude product was chromatographed (EtOAc–hexane, 75:25) to
give 14.
Yield: 300 mg (90%); off-white solid; Rf ca. 0.34 in EtOAc; mp
106.0–107.5 °C.
13C NMR (CDCl3): d = 168.3, 135.2, 128.8, 128.0, 127.8, 77.1, 64.5,
63.8, 49.7, 42.6, 42.0 35.0.
IR (KBr): 3432, 2930, 1638, 1514, 1493, 1251, 1174, 1031, 834,
698 cm–1.
MS (CI; CH4): m/z (%) = 263 (100).
1H NMR (CDCl3): d = 7.38–7.25 (7 H), 6.89 (2 H, br d, J = 8.8 Hz),
5.19 (1 H, dd, J = 6.7, 8.4 Hz), 4.70 (1 H, d, J = 14.4 Hz), 4.58 (2
H, d, J = 14.4 Hz), 4.32 (1 H, br d, J = 7.7 Hz), 3.80 (3 H, s), 3.43
(1 H, m), 3.35–3.21 (3 H), 2.98 (1 H, ddd, J = 6.7, 8.3, 12.8 Hz),
2.72 (1 H, ddd, J = 6.2, 8.5, 12.7 Hz).
13C NMR (CDCl3): d = 168.2, 159.4, 136.2, 132.8, 128.8, 128.1,
127.8, 127.6, 114.0, 78.0, 64.6, 55.3, 49.7, 48.2, 42.6, 41.9.
HRMS (TOF ESI+): m/z calcd for C14H18N2O3 (+H): 263.1390;
found: 263.1389.
Compound 17b
Yield: 17.7 mg (7%); slightly yellow oil; Rf ca. 0.71 in EtOAc. By
1H NMR, the sample contained 5% (ca.1 mg) of diastereomer 17a.
IR (KBr): 3403, 2925, 1637, 1496, 1453, 1355, 731 cm–1.
MS (CI; CH4): m/z (%) = 339 (100).
1H NMR (CDCl3): d = 7.36–7.23 (5 H), 4.70 (1 H, d, J = 14.6 Hz),
4.50 (1 H, d, J = 14.6 Hz), 4.20 (1 H, m), 4.11 (1 H, dd, J = 5.6, 8.7
Hz), 3.77 (1 H, dd, J = 2.9, 12.2 Hz), 3.58 (2 H, m), 3.39–3.21 (2
H), 3.10 (1 H, m), 2.72 (1 H, m), 1.87 (1 H, br s).
13C NMR (CDCl3): d = 168.7, 136.2, 128.7, 128.1, 127.7, 78.5, 63.4,
63.2, 50.0, 48.3, 41.7, 35.2.
Anal. Calcd for C20H22N2O3: C, 70.99; H, 6.55; N, 8.28. Found: C,
70.75; H, 6.69; N, 8.08.
2,5-Dibenzyltetrahydroisoxazolo[2,3-a]pyrazin-4-one (15)
The product was purified by chromatography (EtOAc–hexane,
75:25) to give 15.
MS (CI; CH4): m/z (%) = 263 (100).
Yield: 294 mg (91%); off-white solid; Rf ca. 0.40 in EtOAc; mp
92.0–93.5 °C.
5-Benzyl-2-(2-hydroxyethyl)tetrahydroisoxazolo[2,3-a]pyr-
azin-4-one (18a) and 5-Benzyl-2-(2-hydroxyethyl)tetrahydro-
isoxazolo[2,3-a]pyrazin-4-one (18b)
The crude product was eluted with EtOH–EtOAc (10:90, then
20:80) to separate the diastereomers. The combined mixed fractions
were rechromatographed using EtOH–EtOAc (15:85).
IR (KBr): 3437, 2929, 1634, 1498, 1453, 1259, 1073, 701 cm–1.
1H NMR (CDCl3): d = 7.35–7.19 (10 H), 4.66 (1 H, d, J = 14.7 Hz),
4.48 (1 H, d, J = 14.7 Hz), 4.48 (1 H, m), 4.08 (1 H, app. t, J = 7.7
Hz), 3.36–3.17 (4 H), 3.10 (1 H, m), 2.99 (1 H, dd, J = 6.5, 13.8
Hz), 2.80 (1 H, dd, J = 6.5, 13.8 Hz), 2.66–2.46 (2 H).
13C NMR (CDCl3): d = 168.2, 137.6, 136.2, 129.4, 128.7, 128.5,
128.0, 127.7, 126.6, 77.5, 64.0, 49.6, 48.0, 42.7, 41.1, 38.4.
Synthesis 2005, No. 3, 465–469 © Thieme Stuttgart · New York